Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.78
-0.0400-0.25%
Post-market: 15.780.00000.00%19:40 EDT
Volume:3.43M
Turnover:54.16M
Market Cap:3.18B
PE:-19.09
High:15.96
Open:15.93
Low:15.65
Close:15.82
52wk High:15.97
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.88
T/O Rate:1.75%
Dividend:1
Dividend Rate:6.34%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.03
PE(LYR):-11.03

Loading ...

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

GlobeNewswire
·
Jun 22

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Jun 18

Park Hotels & Resorts, Inc. : Wells Fargo Raises Target Price to $15 From $12

THOMSON REUTERS
·
Jun 18

U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis

Reuters
·
Jun 18

Park Hotels & Resorts Is Maintained at Buy by Ladenburg Thalmann

Dow Jones
·
Jun 17

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

GlobeNewswire
·
Jun 15

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

GlobeNewswire
·
Jun 13

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

GlobeNewswire
·
Jun 11

Nyse Order Imbalance 759031.0 Shares on Sell Side

THOMSON REUTERS
·
Jun 11

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

GlobeNewswire
·
Jun 09

UBS Adjusts Price Target on Park Hotels & Resorts to $14 From $11, Maintains Neutral Rating

MT Newswires Live
·
Jun 08

College Entrance Exam Essays in Beijing and Shanghai Test AI! Three Leading Models Compete: Who Writes the Best Essay?

Deep News
·
Jun 07

Court Orders Gym to Repay Mandatory "Performance Competition" Fees Collected from Employee

Deep News
·
Jun 06

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

GlobeNewswire
·
Jun 06

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

Park Hotels & Resorts updates financial calendar with Q2 earnings release, conference call

Reuters
·
Jun 03

Press Release: Park Hotels & Resorts Inc. Announces Second Quarter 2026 Earnings Conference Call on August 7, 2026

Dow Jones
·
Jun 03

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

GlobeNewswire
·
Jun 03

World Cup Poised to Lift REITs with Full-Service Hotel Exposure -- Market Talk

Dow Jones
·
Jun 03

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Jun 01